# TMO earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TMO) · [Earnings tab](https://www.lopjlb.com/stock/TMO?tab=earnings)

Updated: 2026-10-21T05:57:47

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings calls, Thermo Fisher moved from a largely silent stance in early 2024 to a more assertive outlook by 2026. The company began highlighting strong Q4 2024 performance, delivering 5% revenue growth and expanding margins, and set 2025 guidance for 3‑4% organic revenue growth. Subsequent calls in 2025 showed raised guidance, continued margin expansion, and aggressive capital deployment through acquisitions and buybacks. By Q3 2025 the firm emphasized confidence in a 3‑6% organic growth trajectory, and Q4 2025 reaffirmed a 3‑4% revenue outlook while noting a growing product pipeline. In 2026 Q1, guidance was again raised, the Clario acquisition was completed, and margins were slightly pressured by tariffs and FX, yet productivity offset much of the headwind. Demand remained solid in pharma/biotech and industrial segments, while academic/government, diagnostics, and China markets showed modest declines. New macro‑level concerns emerged in 2026 Q1, including geopolitical conflict, inflation, tariff impacts, and regional demand uncertainty, marking the first explicit mention of such risks. Throughout, product and technology milestones were consistently delivered without reported delays, reinforcing operational execution.

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2026 Q1:** Thermo Fisher delivered strong Q1 with 6% revenue growth, raised 2026 guidance, completed Clario acquisition, end markets on track despite macro uncertainty.
- **2025 Q4:** TMO delivered strong 2025 with 4% revenue growth, 5% EPS growth; initiates 2026 guidance for 3-4% organic revenue growth, 6-8% EPS growth, driven by PPI system, innovation, and M&A; Clario acquisition pending.
- **2025 Q3:** TMO raises 2025 guidance after Q3 beat driven by pharma/biotech strength, margin expansion, and acquisitions; confident in 3-6% organic growth trajectory.
- **2025 Q2:** —
- **2025 Q1:** —
- **2024 Q4:** Thermo Fisher delivered strong Q4 2024 results with 5% revenue growth, 8% EPS growth, and initiated 2025 guidance for 3-4% organic revenue growth and 6-8% adjusted EPS growth, driven by share gains, innovation, and PPI Business System execution.
- **2024 Q3:** —

## Theme arcs

- **Revenue growth guidance confidence** (improving): Guidance moved from vague to maintained and then raised, reflecting growing confidence.
- **Adjusted operating margin trend** (improving): Margins expanded through 2025 before a modest Q1 2026 dip due to tariffs.
- **Capital deployment intensity** (improving): Share repurchases, dividends, and large acquisitions accelerated from 2024 through 2026.
- **End market demand stability** (stable): Pharma/biotech and industrial demand stayed positive; academic/government and diagnostics showed slight weakness.
- **Macro and geopolitical risk exposure** (new): First articulated in 2026 Q1, highlighting conflict, inflation, tariff, and China demand concerns.

## Fear persistence

- **Macro geopolitical conflict** [new]: Cited in 2026 Q1 as modest inflationary pressure and complexity.
- **Inflation risk** [new]: Higher inflation noted affecting supply chain and logistics.
- **Academic/government weakness** [new]: Muted conditions in US and China causing low‑single‑digit decline.
- **China demand uncertainty** [new]: Low‑single‑digit decline expected; management slightly more positive after visit.
- **Tariff impacts** [new]: ~80 bps headwind to adjusted margin in Q1 2026.

## Guidance path

2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:raised → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TMO`